Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DermaRegeon is a topical product developed by CK Regeon designed for hair loss treatment and skin regeneration. It utilizes a first-in-class mechanism that targets the CXXC-type zinc finger protein 5 (CXXC5), which acts as a negative feedback regulator of the Wnt/beta-catenin signaling pathway. The active component, typically the PTD-DBM peptide, interferes with the protein-protein interaction between CXXC5 and Dishevelled (Dvl). By inhibiting this interaction, DermaRegeon restores and activates Wnt/beta-catenin signaling, which is critical for hair follicle development, hair regrowth, and wound healing. The product is being developed as both a therapeutic candidate and a high-functional topical agent for dermatological applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DermaRegeon.